Injectable Therapy for Androgenetic Alopecia: A Systematic Review

This retrospective study found that applying local skin precooling before scalp nerve block significantly reduced injection site pain during PRP mesotherapy for patients with androgenetic alopecia, compared to those who did not receive precooling, thus improving patient comfort and compliance.

Five monthly sessions of minoxidil-dutasteride-copper peptide tattooing significantly improve hair regrowth in men with androgenetic alopecia.

In this systematic review, the researchers observed that topical caffeine preparations appear safe and effective against hair loss, but most studies had low-quality evidence due to design flaws, indicating the need for better-designed trials before drawing definitive conclusions.

In this retrospective analysis, dutasteride mesotherapy was used in 10 patients with androgenetic alopecia and resulted in hair density and width changes measured at the scalp, but specific efficacy results are not detailed in the abstract.

Mesotherapy with bicalutamide has limited effectiveness for female hair loss.

In this study, injections of PRP and MZT products significantly improved hair thickness, density, and count in AGA patients over six months, with variability observed in the extent of improvement between different formulations.

This study reported that the 1565 nm non-ablative fractional laser treatment significantly improved various hair growth indices in patients with androgenetic alopecia compared to 5% minoxidil, demonstrating its superior clinical efficacy and safety for treating this condition.

Microneedling combined with other treatments significantly improves hair growth in people with hair loss and is safe.

This review found that both finasteride and dutasteride are effective for treating hair loss in men with androgenetic alopecia, with dutasteride showing higher efficacy, but noted unclear clinical significance regarding potential negative impacts on reproduction, including possible sexual dysfunction and effects on spermatogenesis.

This review highlights the promising potential of mesotherapy for delivering dutasteride and minoxidil as treatments for androgenetic alopecia, emphasizing the need for more research on drug preparation, delivery, and maintenance to establish its safety and effectiveness.

This study evaluated the clinical outcomes of using tattoo equipment to deliver a combination of minoxidil and dutasteride directly to the scalp over three sessions for treating male androgenetic alopecia, but results are not reported in the abstract.

This comprehensive review analyzes androgenetic alopecia treatments, discussing the mechanisms, costs, efficacy, and safety of FDA-approved drugs like minoxidil and finasteride, as well as newer non-FDA-approved options that have shown effectiveness across various studies.

This study found that bicalutamide mesotherapy resulted in subtle hair density improvements and was well tolerated by premenopausal women with androgenetic alopecia.

This letter to the editor presents no new research results; it discusses a combination of dutasteride intralesional microinjections with oral minoxidil versus oral minoxidil alone for treating androgenetic alopecia in men.

This study concluded that mesotherapy appears effective for treating pattern hair loss, but emphasizes a need for more research comparing it to other treatments due to limited sample sizes.

This study reported 14 cases of frontal edema following mesotherapy for androgenetic alopecia, suggesting clinicians should be aware of this potential side effect.

This review reports that clinical studies generally showed favorable results for microneedling as an adjunct therapy for androgenic alopecia and alopecia areata, despite the low quality of existing data.

This case report highlights two instances of patchy alopecia occurring after mesotherapy with dutasteride, illustrating a possible paradoxical side effect of this treatment for androgenetic alopecia.

In this study, the TRICHOBIOLIGHT protocol showed effectiveness in treating androgenetic alopecia and telogen effluvium, with 82.5% of 103 patients experiencing excellent to good outcomes after mesotherapy and LED photobiostimulation on the scalp.

Platelet-rich plasma with microneedling is effective for hair loss, but the number of sessions needed varies.

In this study, intradermal injections of 0.5% minoxidil significantly improved hair growth and volume in women with female androgenetic alopecia compared to a placebo, with a good safety profile reported.

This study found that using a vibration anesthetic device during scalp mesotherapy significantly reduced pain in patients with androgenetic alopecia and alopecia areata compared to the non-vibration side.

This study found that metabolic syndrome negatively affected the response to intradermal dutasteride injection in female pattern hair loss, with participants showing reduced terminal hair and increased vellus hair compared to those without the syndrome.

This case report observed significant improvement in hair density and thickness in a male patient with androgenetic alopecia following the addition of mesotherapy, alongside topical minoxidil and oral finasteride, over 20 sessions, with no side effects reported.

This study observed no significant improvement of mesotherapy over 5% topical minoxidil for male androgenic alopecia, despite a small increase in hair shaft diameter variation with mesotherapy.

This meta-analysis suggests that individuals with vertex baldness may have a higher risk of prostate cancer, though overall baldness is not significantly associated with prostate cancer risk.

This article discusses treatments for female pattern hair loss, highlighting that oral antiandrogens and topical minoxidil can effectively arrest progression and reverse miniaturization in many patients with mild-to-moderate cases, but it reports no new clinical results.

This review suggests that PRP injections may be effective in promoting hair regrowth, reducing hair loss, and increasing hair thickness in patients with androgenic alopecia.

This study reports that mesotherapy for androgenetic alopecia may paradoxically lead to hair loss and scarring, highlighting the need for improved regulation and monitoring of this treatment.

This review discusses clinical features, differential diagnosis, and treatments for female pattern hair loss, emphasizing the use of 2% topical Minoxidil and exploring alternative off-label therapies.

This study found that mesotherapy with a dutasteride-containing preparation improved hair growth indicators in female pattern hair loss better than saline, with minimal side effects and greater effectiveness in patients with shorter disease duration.

This study measured the lengths and depths of different portions of occipital scalp hair follicles and suggested cutting below 1 mm for hair regeneration procedures to avoid damaging the bulge zone.

This report highlights two cases where patchy alopecia developed after mesotherapy for androgenetic alopecia, indicating potential risks associated with this treatment.

Minoxidil can cause skin allergy; use alternative solvents or treatments if allergic.